RACURA ONCOLOGY

ASX Announcement

Results of Annual General Meeting

23 November 2026

Racura Oncology Limited ("Racura" or the "Company") advises that its Annual General Meeting of shareholders was held today at 12.00 pm AEDT.

The resolutions were voted in accordance with the Notice of Annual General Meeting previously advised to the Australian Securities Exchange.

All resolutions were carried on a poll, with Resolution 8 (Selective Share Buty-Back from Dr Daniel Tillett) and Resolution 9 (Selective Share Buty-Back from Mr Phillip Lynch) being carried by a sufficient majority as special resolutions.

Further information required by section 251AA(2) of the Corporations Act 2001 (Cth) is attached to this announcement.

-ENDS-

About Racura Oncology

Racura Oncology (ASX: RAC) is a late-stage clinical biopharmaceutical company with a mission to silence cancer.

Racura's lead asset, (E,E)-bisantrene, is a clinically derisked small-molecule anticancer agent that primarily acts by stabilising G4-DNA and RNA structures, driving potent inhibition of c-MYC gene expression, a key cancer gene dysregulated in up to 70% of all cancers. Bisantrene has shown therapeutic activity in cancer patients and has a well-characterised safety profile. Racura's discoveries have supported composition-of-matter IP filings that, if granted, could provide up to 20 years of patent protection for (E,E)-bisantrene.

Racura is advancing RC220, its proprietary formulation of (E,E)-bisantrene, to address significant unmet need across multiple MYC-driven oncology indications. The Company's clinical programs include the EMILI Phase 2b/3 trial in acute myeloid leukaemia, the HARNESS Phase 1 trial in combination with osimertinib for EGFRm NSCLC, and the CPACS Phase 1 trial in combination with doxorubicin, where Racura aims to deliver both anthracycline cardioprotection and enhanced anticancer activity.

Racura has collaborated with Astex, Emory University, Purdue University, MD Anderson Cancer Center, Sheba Medical Center, University of North Carolina School of Medicine, University of Wollongong, and University of Newcastle. Racura is actively exploring partnerships, licence agreements, and potential

commercial merger and acquisition opportunities to accelerate global patient access to RC220. Learn more at www.racuraoncology.com.

If you have any questions on this announcement, or any past Racura Oncology announcements, please visit the Company's Interactive Announcements page.

Racura encourages all investors to go paperless by registering their details with the Company's share registry, Automic Registry Services, at www.automicgroup.com.au.

Release authorised by

Daniel Tillett, CEO/MD

info@racuraoncology.com

Media Contact

Cherie Hartley +61 418 737 020

cherie.hartley@irdepartment.com.au

Results of Meeting

Racura Oncology Ltd

Annual General Meeting

Monday, 23 November 2026

Automic
GPO Box 5193, Sydney, NSW 2001
P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world)
F +61 (0)2 8583 3040 E hello@automic.com.au
ABN 27 152 260 814

In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

		Proxy Votes (as at proxy voting close)				Poll Results (if applicable)			Results
Resolution	**Decided by Show of Hands (S) or Poll (P)**	**FOR**	**AGAINST**	**ABSTAIN**	**PROXY'S DISCRETION**	**FOR**	**AGAINST**	**ABSTAIN**	**OUTCOME**
1 ADOPTION OF REMUNERATION REPORT	P	37,340,132 92.01%	3,108,033 7.66%	419,050	135,835 0.33%	41,406,120 93.02%	3,108,033 6.98%	419,050	-
2 RE-ELECTION OF DR SERGE SCROFANI	P	51,217,540 95.77%	2,164,301 4.05%	7,615,568	100,371 0.19%	55,450,118 96.24%	2,164,301 3.76%	7,615,568	Carried
3 ISSUE OF OPTIONS TO DR PETER SMITH	P	36,386,814 89.62%	4,115,271 10.14%	400,094	100,871 0.25%	40,255,653 90.39%	4,277,456 9.61%	592,715	Carried
4 ISSUE OF OPTIONS TO DR DANIEL TILLETT	P	36,652,553 90.44%	3,771,346 9.31%	478,280	100,871 0.25%	40,521,392 91.15%	3,933,531 8.85%	670,901	Carried
5 ISSUE OF OPTIONS TO DR MEGAN BALDWIN	P	22,630,225 68.67%	9,813,911 29.78%	8,048,032	510,882 1.55%	25,837,609 70.57%	10,773,008 29.43%	8,515,207	Carried
6 ISSUE OF OPTIONS TO DR SERGE SCROFANI	P	28,188,671 85.08%	4,807,734 14.51%	7,870,734	135,911 0.41%	32,077,450 86.58%	4,969,919 13.42%	8,078,455	Carried
7 APPROVAL TO ISSUE OPTIONS TO DR PETER SMITH IN LIEU OF CASH BONUS ENTITLEMENT	P	36,922,666 95.17%	1,774,280 4.57%	2,205,233	100,871 0.26%	39,979,005 95.75%	1,774,280 4.25%	3,372,539	Carried
8 SELECTIVE SHARE BUY-BACK FROM DR DANIEL TILLETT - SPECIAL RESOLUTION	P	39,349,201 97.55%	852,071 2.11%	666,367	135,411 0.34%	43,406,040 98.07%	855,129 1.93%	874,088	Carried
9 SELECTIVE SHARE BUY-BACK FROM MR PHILLIP LYNCH - SPECIAL RESOLUTION	P	58,781,930 97.37%	1,079,101 1.79%	726,367	510,382 0.85%	63,406,361 98.32%	1,082,159 1.68%	741,467	Carried